[Renin-angiotensin system blockers and COVID-19 infection]

doi:10.1016/j.hipert.2020.04.002

Editorial

. 2020 Jul-Sep;37(3):99-100.

doi: 10.1016/j.hipert.2020.04.002. Epub 2020 Apr 16.

[Renin-angiotensin system blockers and COVID-19 infection]

[Article in Spanish]

L M Ruilope¹, J A Garcia Donaire², A de la Sierra³

Affiliations

¹ Cardiorenal Translational Laboratory, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, España; Unidad de Hipertensión, Hospital Universitario 12 de Octubre, Madrid, España; Universidad Europea Madrid, Madrid, España; CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address: ruilope@icloud.com.
² Unidad de Hipertensión Arterial, Hospital Clínico San Carlos, Madrid, España; Unidad de Hipertensión. Servicio de Medicina Interna, Hospital Mutua Terrassa, Terrassa, Barcelona, España.
³ Departament de Medicina, Universitat de Barcelona, Barcelona, España; Unidad de Hipertensión, Servicio de Medicina Interna, Hospital Mutua Terrassa, Terrassa, España.

PMID: 32448641
PMCID: PMC7161518
DOI: 10.1016/j.hipert.2020.04.002

Editorial

[Renin-angiotensin system blockers and COVID-19 infection]

[Article in Spanish]

L M Ruilope et al. Hipertens Riesgo Vasc. 2020 Jul-Sep.

. 2020 Jul-Sep;37(3):99-100.

doi: 10.1016/j.hipert.2020.04.002. Epub 2020 Apr 16.

Authors

L M Ruilope¹, J A Garcia Donaire², A de la Sierra³

Affiliations

¹ Cardiorenal Translational Laboratory, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, España; Unidad de Hipertensión, Hospital Universitario 12 de Octubre, Madrid, España; Universidad Europea Madrid, Madrid, España; CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address: ruilope@icloud.com.
² Unidad de Hipertensión Arterial, Hospital Clínico San Carlos, Madrid, España; Unidad de Hipertensión. Servicio de Medicina Interna, Hospital Mutua Terrassa, Terrassa, Barcelona, España.
³ Departament de Medicina, Universitat de Barcelona, Barcelona, España; Unidad de Hipertensión, Servicio de Medicina Interna, Hospital Mutua Terrassa, Terrassa, España.

PMID: 32448641
PMCID: PMC7161518
DOI: 10.1016/j.hipert.2020.04.002

No abstract available

PubMed Disclaimer

References

1. Somerstein R. Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ. 2020;368:m810. https://www.bmj.com/content/368/bmj.m810/rr-2 - PubMed
1. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet. 2020;8:e21. doi: 10.1016/S2213-2600(20)30116-8. - DOI - PMC - PubMed
1. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 doi: 10.1002/ddr.21656. - DOI - PMC - PubMed
1. Danser A.H.J., Epstein M., Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic. At present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75 doi: 10.1161/HYPERTENSIONAHA.120.15082. - DOI - PMC - PubMed
1. Bavishi C., Maddox T.M., Messerli F.H. Coronavirus Disease (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1282. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Somerstein R. Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ. 2020;368:m810. https://www.bmj.com/content/368/bmj.m810/rr-2 - PubMed

[2] Somerstein R. Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ. 2020;368:m810. https://www.bmj.com/content/368/bmj.m810/rr-2 - PubMed

[3] Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet. 2020;8:e21. doi: 10.1016/S2213-2600(20)30116-8. - DOI - PMC - PubMed

[4] Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet. 2020;8:e21. doi: 10.1016/S2213-2600(20)30116-8. - DOI - PMC - PubMed

[5] Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 doi: 10.1002/ddr.21656. - DOI - PMC - PubMed

[6] Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 doi: 10.1002/ddr.21656. - DOI - PMC - PubMed

[7] Danser A.H.J., Epstein M., Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic. At present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75 doi: 10.1161/HYPERTENSIONAHA.120.15082. - DOI - PMC - PubMed

[8] Danser A.H.J., Epstein M., Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic. At present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75 doi: 10.1161/HYPERTENSIONAHA.120.15082. - DOI - PMC - PubMed

[9] Bavishi C., Maddox T.M., Messerli F.H. Coronavirus Disease (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1282. - DOI - PubMed

[10] Bavishi C., Maddox T.M., Messerli F.H. Coronavirus Disease (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1282. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

[Renin-angiotensin system blockers and COVID-19 infection]

Affiliations

[Renin-angiotensin system blockers and COVID-19 infection]

Authors

Affiliations

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources